TLSI
NASDAQ · Biotechnology
Trisalus Life Sciences Inc
$4.75
+0.07 (+1.50%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 47.23M | 45.65M | 46.65M |
| Net Income | -3,256,844 | -3,940,718 | -4,180,453 |
| EPS | — | — | — |
| Profit Margin | -6.9% | -8.6% | -9.0% |
| Rev Growth | +7.1% | +0.6% | -1.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 115.31M | 91.39M | 101.31M |
| Total Equity | 107.73M | 99.32M | 108.24M |
| D/E Ratio | 1.07 | 0.92 | 0.94 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -4,196,050 | -4,663,249 | -4,114,414 |
| Free Cash Flow | -5,024,799 | -4,621,021 | -5,351,943 |